Top 20 medications by proportion of QREs with harm (minimum of 10 QREs reported with harm)
| Medication | ATC classification | Number (%) of QREs with harm | Number (%) of QREs | Proportion of QREs with harm (%) |
| Methadone | N07BC02 | 19 (1.79) | 184 (0.18) | 10.33 |
| Risperidone | N05A×08 | 11 (1.03) | 313 (0.30) | 3.51 |
| Warfarin | B01AA03 | 22 (2.07) | 746 (0.72) | 2.95 |
| Morphine | N02AA01 | 16 (1.50) | 568 (0.55) | 2.82 |
| Atenolol | C07AB03 | 14 (1.32) | 544 (0.52) | 2.57 |
| Citalopram | N06AB04 | 27 (2.54) | 1261 (1.21) | 2.14 |
| Norgestimate and oestrogen | G03AB11 | 10 (0.94) | 528 (0.51) | 1.89 |
| Levothyroxine sodium | H03AA01 | 46 (4.32) | 2433 (2.34) | 1.89 |
| Gliclazide | A10BB09 | 13 (1.22) | 694 (0.67) | 1.87 |
| Ramipril | C09AA05 | 14 (1.32) | 778 (0.75) | 1.80 |
| Sulfamethoxazole and trimethoprim | J01EE01 | 13 (1.22) | 808 (0.78) | 1.61 |
| Furosemide | C03CA01 | 15 (1.41) | 1024 (0.99) | 1.46 |
| Hydromorphone | N02AA03 | 25 (2.35) | 1826 (1.76) | 1.37 |
| Venlafaxine | N06A×16 | 14 (1.32) | 1143 (1.10) | 1.22 |
| Amlodipine | C08CA01 | 12 (1.13) | 988 (0.95) | 1.21 |
| Sertraline | N06AB06 | 10 (0.94) | 845 (0.81) | 1.18 |
| Naproxen | M01AE02 | 13 (1.22) | 1236 (1.19) | 1.05 |
| Prednisone | H02AB07 | 13 (1.22) | 1254 (1.21) | 1.04 |
| Pantoprazole | A02BC02 | 10 (0.94) | 1044 (1.01) | 0.96 |
| Rosuvastatin | C10AA07 | 18 (1.69) | 1905 (1.84) | 0.94 |
| Total | – | 1064* | 103 812† | – |
*Total of all reported medications in QREs with harm (excluding free-form entry of medication name); the reporter can input more than one medication per QRE; hence, the total number of QREs associated with patient harm in this table is greater than what is shown in the results section.
†Total of all reported medications in QREs (excluding free-form entry of medication name). The reporter can input more than one medication per QRE; hence, the total number of QREs in this table is greater than what is shown in the results section.
ATC, Anatomical Therapeutic Chemical; QREs, quality-related events.